Ansa Biotechnologies vs Veeva Systems
Side-by-side comparison of AI visibility scores, market position, and capabilities
Enzymatic DNA synthesis company using TdT enzymes to write longer, higher-fidelity DNA; $68M Series B for synthetic biology and therapeutic applications.
About
Ansa Biotechnologies is a synthetic DNA synthesis company developing enzymatic DNA writing technology to overcome the length and quality limitations of chemical DNA synthesis. Founded in 2021 and headquartered in Emeryville, California, Ansa uses engineered terminal deoxynucleotidyl transferase (TdT) enzymes rather than phosphoramidite chemistry to build DNA strands, enabling synthesis of longer sequences with higher fidelity and fewer toxic reagents. The company emerged from research at UC Berkeley and Lawrence Berkeley National Laboratory.
Veeva Systems (VEEV) reported $2.7B revenue in FY2025, up 14% YoY. #1 cloud platform for life sciences. ~8,000 employees. HQ: Pleasanton, CA. Market cap ~$40B.
About
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executive) and Matt Wallach, Veeva built its platform on Salesforce and later developed its own Vault cloud infrastructure. The company became a public benefit corporation (PBC) in 2021. Veeva reported revenues of $2.7B in fiscal year 2025 (ending January 2025), up 14% year-over-year, with a market capitalization of approximately $40B.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.